Best in Biotech 24 Jul 2025
Which biotech companies are gaining traction in genetic diseases?
Discover twelve companies focused on genetic diseases that managed to close funding rounds in the last two years.
About
After I graduated with a master’s degree in European Law from the
University of Tours, I decided to study journalism at the All Media
Journalism Institute of Lille. During this time, I discovered the healthcare
innovation ecosystem and enjoyed writing about it for Eurasanté, a French
healthcare cluster. I am interested in different subjects other than
healthcare and biotechnology: cinema, sports, photography… Journalism
had always been at the back of my mind, and I am delighted to write for
Labiotech as a junior reporter. When I am not working you might find me on the tennis court or picking up the next piece of furniture I will renovate.
Articles by Jules Adam
Best in Biotech 23 Jul 2025
Biotech stars of 2024, did they shine or fade in 2025?
Find out if the biotech companies Labiotech designated as the ones to keep an eye on in 2024 held up to our expectation in 2025.
In Depth 18 Jul 2025
Hyderabad’s Genome Valley, biopharma’s scale-up hub
Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and gene therapy.
Podcast 18 Jul 2025
Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy
This week, I talked to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation.
News and Trends 10 Jul 2025
Radiopharma’s new wave: Nuclidium and Actithera raise the stakes
Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.
In Depth 9 Jul 2025
New hope for CIPN: Can emerging therapies ease chemotherapy’s nerve damage?
Delve into the growing field of CIPN, the most common side effect of chemotherapy, as we are getting closer to a first approval.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 4 Jul 2025
14 biotech companies to know in the Boston area in 2025
Explore Boston’s vibrant biotech landscape with fourteen innovative companies leading the charge in life sciences research.
In Depth 1 Jul 2025
Is an HIV cure possible? The future of HIV therapy
Delve into the field of HIV treatment development. Since the virus was discovered, treatments have improved, but are we close to a cure?
Podcast 27 Jun 2025
Humacyte: Saving lives with lab-grown blood vessels in conflict zones
This week we spoke to Humacyte founder, Laura Niklason about the real-world applications for lab-grown blood vessels in conflict zones.
News and Trends 23 Jun 2025
Turning plastic into medicine: Closing the loop on pharma production
Find out about the University of Edinburgh’s work to convert our common plastic wast into the wildly used paracetamol.
In Depth 18 Jun 2025
From undruggable to oral therapy: The rise of STAT6 degraders
Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.
In Depth 16 Jun 2025
Did Novo open the Canadian market to GLP-1 generics?
Find out if Novo’s GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee?
ADVERTISEMENT
